Sandoz core EPS down 22% in 2023
Volume contributed 10 points to growth, partially offset by price erosion of three points. Growth was driven by strong demand, product launches and the ongoing performance of Omnitrope and Hyrimoz.
For 2024, the Swiss manufacturer of generics and biosimilars is targeting revenue growth 'in the mid-single-digit range at constant exchange rates' and a core EBITDA margin of around 20%.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction